Abstract: The present invention is directed to the identification of novel targets for therapeutic intervention and prevention of ischemia and reperfusion injury resulting from hypoxia, stroke, heart attack, chronic kidney failure or organ transplantation. In particular, the present invention is directed to the identification of novel targets for the prevention of reperfusion injury following organ transplantation. The present invention is further directed to methods of high-throughput screening for test compounds capable of inhibiting activity of proteins encoded by the novel targets by combining the test compounds and the protein and detecting binding. Moreover, the present invention is also directed to methods that can be used to assess the efficacy of test compounds and therapies for the ability to inhibit organ damage resulting from reperfusion injury. Methods for determining the prognosis of long term organ survival in a subject having an organ transplant are also described.

Abstract: The present invention is directed to novel methods for diagnosis and prognosis of Systemic lupus erythematosus by identifying differentially expressed genes. Moreover, the present invention is also directed to methods that can be used to screen test compounds and therapies for the ability to inhibit systemic lupus erythematosus. Additionally, methods and molecule targets (genes and their products) for therapeutic intervention in systemic lupus erythematosus are described.

Abstract: The present invention is directed to novel methods for diagnosis and prognosis of Systemic lupus erythematosus by identifying differentially expressed genes. Moreover, the present invention is also directed to methods that can be used to screen test compounds and therapies for the ability to inhibit systemic lupus erythematosus. Additionally, methods and molecule targets (genes and their products) for therapeutic intervention in systemic lupus erythematosus are described.